一种用于在初级保健中识别非特异性肌肉骨骼症状者中抗CCP阳性者的多变量预测模型
研究开发了用于初级保健非特异性肌肉骨骼症状人群的抗CCP阳性预测模型,纳入6879例,203例(2.95%)抗CCP阳性。模型保留11个预测因子,AUROC为0.65(95%CI 0.61, 0.69)。采用4%决策阈值时,模型推荐1288例(18.7%)进行抗CCP检测,其中78例(6.1%)阳性,阈值以下为125/5591(2.2%)阳性。
要点
- 模型纳入男性、RA一级亲属、曾吸烟及多部位关节痛共11个预测因子,AUROC为0.65(95%CI 0.61, 0.69)。
- 4%阈值下推荐18.7%参与者检测抗CCP,该组阳性率6.1%,阈值以下阳性率2.2%。
- 阈值以上且抗CCP阳性者12个月内32.1%诊断炎症性关节炎/RA,抗CCP阴性者仅0.4%。
核心结论
- 在初级保健中对非特异性肌肉骨骼症状者进行靶向抗CCP检测可能有助于早期识别RA风险人群,促进风湿科转诊以早期诊断和启动改善病情抗风湿药治疗。
研究设计与样本
- 研究纳入年龄≥16岁、新发非特异性肌肉骨骼症状且无临床滑膜炎病史的参与者,完成症状问卷并检测抗CCP。
- 模型开发采用LASSO惩罚逻辑回归,通过受试者工作特征曲线下面积(AUROC)和决策曲线分析评估性能,用自助法和交叉验证估计过拟合。
- 参与者随访12个月,观察RA或血清阴性/未分化炎症性关节炎诊断。
主要发现
- 分析纳入6879例参与者,其中203例(2.95%)抗CCP阳性。
- 模型保留11个预测因子:男性、RA一级亲属、曾吸烟以及背部、颈部、肩部、腕部、手/手指、拇指、膝部、足/趾关节痛。
- AUROC为0.65(95%CI 0.61, 0.69,乐观度=0.03)。
- 采用4%决策阈值,模型推荐1288例(18.7%)进行抗CCP检测,其中78例(6.1%)抗CCP阳性;阈值以下者125/5591(2.2%)抗CCP阳性。
- 净获益为0.0040(校正后0.0020)。
临床怎么用
- 作者认为,在初级保健中对非特异性肌肉骨骼症状者进行靶向抗CCP检测可能有助于早期识别RA风险人群,促进风湿科转诊以早期诊断和启动改善病情抗风湿药治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We aimed to develop a prediction model identifying people presenting to primary care with musculoskeletal symptoms likely to be anti-CCP positive and therefore at risk of developing RA. METHODS: Participants aged ≥16 years, with new-onset non-specific musculoskeletal symptoms and no history of clinical synovitis, completed a symptom questionnaire and had an anti-CCP test. Model development used LASSO-penalized logistic regression, performance was assessed using area under the receiver operating characteristic curve (AUROC) and decision curve analysis, model over-fit was estimated using bootstrapping and cross-validation. Participants were followed-up at 12 months for RA or seronegative/undifferentiated inflammatory arthritis diagnosis. RESULTS: Analysis included 6879 participants; 203 (2.95%) of whom were anti-CCP positive. Eleven predictors were retained: male sex, first-degree relative with RA, ever smoked and joint pain in: back, neck, shoulders, wrists, hands/fingers, thumbs, knees, feet/toes. AUROC was 0.65 (95% CI 0.61, 0.69, optimism = 0.03). Using a 4% decision threshold, the model recommended an anti-CCP test in 1288 (18.7%) participants, 78 (6.1%) of whom were anti-CCP positive, compared with 125/5591 (2.2%) below the threshold. Net benefit was 0.0040 (0.0020 corrected). Forty-eight participants were diagnosed with inflammatory arthritis/RA within 12 months. Of those who were above the threshold and anti-CCP positive, 32.1% developed inflammatory arthritis/RA compared with 0.4% of those who were anti-CCP negative. Of those below the threshold, 0.3% were diagnosed with inflammatory arthritis/RA. CONCLUSIONS: Targeted anti-CCP testing in primary care may aid earlier identification of people at risk of RA, prompting specialist referral to rheumatology for earlier diagnosis and initiation of disease-modifying therapy.
引用
- Siddle HJ, Wilson M, Nam JL, et al. A multivariable prediction model to identify anti-CCP positive people in those with non-specific musculoskeletal symptoms in primary care. Rheumatology (Oxford). 2025. PMID: 39656784. doi:10.1093/rheumatology/keae653
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。